Structural change in CTLA-4 protein due to the polymorphism was predicted and investigation for CTLA-4 structural changes on the therapeutic efficiency of HCC first and second line therapeutics was carried out. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.